Immune Pharmaceuticals Initiates Phase 2 Clinical Trial with Bertilimumab for Ulcerative Colitis Treatment

Immune Pharmaceuticals Initiates Phase 2 Clinical Trial with Bertilimumab for Ulcerative Colitis Treatment
Immune Pharmaceuticals, Inc. recently announced the enrollment of the first patient in its Phase 2 clinical trial to assess the safety and efficacy of the first-in-class, entirely human monoclonal antibody bertilimumab for the treatment of ulcerative colitis (UC). “We recently announced U.S. IND [Investigational New Drug] acceptance by the FDA for bertilimumab in bullous pemphigoid, and today,

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *